PANG — Pangaea Oncology SA Income Statement
0.000.00%
Last trade - 00:00
- €59.07m
- €56.61m
- €4.37m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.06 | 3.32 | 4.1 | 4.6 | 4.37 |
Cost of Revenue | |||||
Gross Profit | 2.9 | 3.17 | 3.4 | 3.8 | 2.17 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 4.84 | 8.11 | 5.76 | 5.23 | 6.88 |
Operating Profit | -1.78 | -4.79 | -1.66 | -0.625 | -2.51 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.13 | -4.98 | -1.91 | -1.1 | -2.84 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.25 | -4.84 | -1.79 | -0.642 | -2.72 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1.25 | -4.84 | -1.79 | -0.642 | -2.71 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.25 | -4.84 | -1.79 | -0.642 | -2.71 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.093 | -0.188 | -0.095 | -0.026 | -0.088 |
Dividends per Share |